Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics Stock Forecast

CMMB's stock price has decreased by -59.57% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Chemomab Therapeutics stock has a target of 25, which predicts a 1,370.59% increase from the current stock price of 1.7.

Price Target: $25 (+1,370.59%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$25	$25	$25	$25
Change	+1370.6%	+1370.6%	+1370.6%	+1370.6%

* Price targets were last updated on Aug 27, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Chemomab Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	1	1	1	1	1	0
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jeff Jones Oppenheimer	Oppenheimer	Buy Maintains $10 → $25	Buy	Maintains	$10 → $25	+1,370.59%	Aug 27, 2025
Jeff Jones Oppenheimer	Oppenheimer	Buy Maintains $44 → $40	Buy	Maintains	$44 → $40	+2,252.94%	May 16, 2025
Michael Okunewitch Maxim Group	Maxim Group	Strong Buy Maintains $16 → $28	Strong Buy	Maintains	$16 → $28	+1,547.06%	Feb 20, 2025
Jeff Jones Oppenheimer	Oppenheimer	Buy Reiterates $52 → $44	Buy	Reiterates	$52 → $44	+2,488.24%	Nov 15, 2024
Michael Okunewitch Maxim Group	Maxim Group	Strong Buy Initiates $16	Strong Buy	Initiates	$16	+841.18%	May 13, 2024

More Analyst Ratings

Financial Forecast

• Revenue This Year:
  n/a
• Revenue Next Year:
  n/a
• EPS This Year:
  -1.48

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-4.81	-9.72	-8.25	-3.11	-1.41	-1.48	-1.26
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	-0.95	-1.30
Avg	-1.48	-1.26
Low	-1.96	-1.22

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.